Compare Chevron Corp (CVX) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Chevron Corp vs DexCom, Inc. — how do they compare? Chevron Corp trades at $213.08 (market cap $414.98B), while DexCom, Inc. trades at $84.88 (market cap $31.86B). The key difference: Chevron Corp is far larger — about 13× DexCom, Inc.'s market cap, and Chevron Corp pays a 3.37% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Chevron Corp for 101 Days and DexCom, Inc. for 62 Days on average.
| CVX | DXCM | |
|---|---|---|
Market Cap | $414.98B | $31.86B |
Volume | 7,575,112 | 3,607,070 |
Sector | Energy | Health |
52-Week High | $217.73 | $92.34 |
52-Week Low | $146.72 | $54.84 |
Typical Hold Time | 101 Days | 62 Days |
Enterprise Value | $443.52B | $31.32B |
Dividend Yield | 3.37% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVX trades at $205.19, down 1.17% on the day, with a neutral technical signal and bullish moving averages. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $6.06 exceeding the $5.55 forecast. Revenue declined to $184.43B in 2025, but a rebound to $208.7B is projected for 2026. Analyst consensus is a Buy with a $208.31 price target, and the company maintains a strong balance sheet with $6.79B in cash.
CVX presents a mixed outlook; earnings beats and a favorable analyst consensus support upside, but declining revenue and net income margins pose risks. High oil prices and strategic investments, like the $13.8B Argentina project, offer growth potential, yet geopolitical tensions and volatile energy markets remain headwinds for shareholders.
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.
The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Chevron Corp
Chevron Corporation is an integrated energy company with operations in countries located around the world. The Company produces and transports crude oil and natural gas. Chevron also refines, markets, and distributes fuels, as well as is involved in chemical and mining operations, power generation, and energy services.
Read more on CVX →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
